Trial Profile
A Feasibility Study to Evaluate the Effect of Ustekinumab on Systemic and Vascular Inflammation Associated with Metabolic Syndrome and Cardiovascular Disease in Patients with Moderate to Severe Psoriasis using 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography [18F-FDG PET/CT]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2018
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 17 Mar 2018 According to results published in the Journal of the American Academy of Dermatology, patients and healthy individuals were referred and screened for the study between Mar 2013 and Feb 2015.
- 17 Mar 2018 Results published in the Journal of the American Academy of Dermatology.
- 08 Jun 2017 New trial record